& Events
& Events
News
& Events
Sep 29, 2020 Inversago Pharma Initiates Clinical Trials, with a Phase 1 study of INV-101, the Company’s Lead Peripheral CB1 Blocker
MONTREAL (CANADA) – September 29, 2020 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has initiated a Phase 1 clinical trial of INV-101, the Company’s peripherally-acting CB1 blocker, which is being developed for the treatment of Prader-Willi syndrome (PWS) and non-alcoholic steatohepatitis (NASH). The trial will evaluate […]
Sep 28, 2020 Media talk about Inversago Pharma
MONTREAL (CANADA) – September 28, 2020 – The Globe & Mail, BioteCanada’s Insights magazine and Endpoints News recently published articles about Inversago Pharma. The Globe & Mail – Investors bet $35-million on Montreal startup’s effort to revive failed class of weight-loss drugs by Sean Silcoff Insights Magazine – Fall 2020, Pages 80-81 – The Peripheral […]
Sep 8, 2020 Inversago Pharma closes US$35M Series B financing round and expands Board of Directors
Funds to pursue development of INV-101 and other promising peripheral CB1 blockers to clinical proof-of-concept, as well as to expand the Company’s operations. Board of Inversago strengthened with the appointment of three new directors. MONTREAL (CANADA) – September 8th, 2020 –Inversago Pharma Inc. (“Inversago” or “the Company”), the peripheral CB1 blockade company, today announced it […]
